Divi's Laboratories (BOM:532488) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:532488 Divi's Laboratories Ltd BOM:532488
93 GF Score
Price ₹8,056.65
GF Value ₹6,796.35
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Divi's Laboratories FFO?

FFO (Funds from operations) only applies to REITs.

BOM:532488
93GF Score
Divi's Laboratories Ltd BOM:532488
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Divi's Laboratories (BOM:532488) Overvalued in 2026?

Based on GuruFocus' analysis, Divi's Laboratories stock appears to be overvalued. The current stock price of ₹8,056.65 is trading 18.5% above its estimated GF Value™ of ₹6,796.35. GuruFocus considers Divi's Laboratories to be Modestly Overvalued.

Key valuation signals for BOM:532488:

  • FFO:
  • GF Value™: ₹6,796.35 vs. price of ₹8,056.65 (18.5% above fair value)
  • GF Score™: 93/100 with 7 warning signs

No single metric tells the full story. See the BOM:532488 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Divi's Laboratories Business Description

Other Exchanges DIVISLAB:India
Address Cyber Hills, Divi Towers, 1-72/23(P)/DIVIS/303, Gachibowli, Hyderabad, TG, IND, 500032
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. It is engaged in the manufacture of Active Pharmaceutical ingredients (API), Intermediates, and Nutraceutical ingredients, with a predominance in exports. It also, through its custom synthesis, supports pharma companies for their patented products business from gram-scale requirements for clinical trials to launch, as well as late-life cycle management. Geographically, the company derives maximum revenue from Europe, and the rest from America, India, Asia (excluding India), and the Rest of the world.
93GF Score

Get the complete analysis for BOM:532488

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹8,056.65
Price
₹6,796.35
GF Value